Market Overview

An 'Unsung Potential Winner,' ObsEva Initiated At Buy

Share:
Related
The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares
The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results
An In-Depth Look At ObsEva (Seeking Alpha)

Terming Obseva SA (NASDAQ: OBSV) as an unsung potential winner in women's health, H.C. Wainwright initiated coverage of the Swiss company at a Buy, with $27 price target.

Analyst Raghuram Selvaraju believes OBE2109, which the company in-licensed from Japan's Kissei Pharmaceutical outside Japan and certain other Asian countries, could be preferred for various reasons. OBE 2109 is a gonadotropin hormone-releasing hormone receptor antagonist, targeting uterine fibroids and endometriosis.

The analyst indicated OBE2109 offers the flexibility for using at both a lower dose, which wouldn't need estrogen, and a higher dose that can be combined with estrogen. Additionally, the analyst said it has a favorable pharmokinetic profile, with low volume of distribution, leading to superior safety. It is orally administered, with once-daily dosing.

See Also: Attention To Details: Neos' ADHD Portfolio

H.C. Wainwright noted that OBE2109 has entered phase 3 trials for uterine fibroids and is in phase 2b testing for endometriosis. The firm expects the treatment candidate to be launched in 2021 in the U.S. and 2022 in Europe, with peak sales estimated at $1.3 billion in ObsEva territories.

The Pipeline

  • OBE2109 – phase 2b study for endometriosis – data to be released in first half of 2018
  • OBE2109 – phase 3 study for uterine fibroids – data to be released in late 2019
  • OBE001 – phase 3 trials for this oxytocin receptor antagonist is in pivotal testing for enhancement in in vitro fertilization; data to be released in mid-2018

Thus, the firm said the next 12-18 months would be catalyst-rich for the company.

Undervalued Shares

H.C. Wainwright noted that ObsEva traded at an enterprise value of $70 million compared to Myovant Sciences Ltd (NYSE: MYOV), which is valued at $560 million, and with its relugolix, has preceded ObsEva in the GnRH receptor antagonist market only by a year.

The firm also thinks ObsEva pipeline beyond OBE2109 is more mature than that of Myovant. Additionally, the firm believes the stock's plunge to $5 from its offer price of $15 per share is not justified, given the company's strong competitive positioning.

At time of writing, ObsEva shares were up 28 percent to $8.10.

Latest Ratings for OBSV

DateFirmActionFromTo
Sep 2018JP MorganInitiates Coverage OnOverweight
Aug 2018WedbushInitiates Coverage OnOutperform
Jul 2018Credit SuisseInitiates Coverage OnOutperform

View More Analyst Ratings for OBSV
View the Latest Analyst Ratings

Posted-In: HC Wainwright Raghuram SelvarajuAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (MYOV + OBSV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NFLXKeyBancDowngrades0.0
DLTRKeyBancMaintains108.0
LRCXKeyBancMaintains231.0
AKRXPiperJaffrayUpgrades9.0
ANETBMO CapitalUpgrades279.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

U.S. Crude Climbs After EIA Reports Drop In Production

5 Reasons Why Sallie Mae (SLM) Is An Attractive Pick Now